📰 Nasdaq Brns News
Nasdaq Brns News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Brns. Real-time updates on events, politics, business and more.
April 19, 2024
Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a research note issued to investors on Friday, Benzinga reports. They presently have a $8.00 price target on the stock. HC Wainwright’s price target would indicate a potential upside of 218.73% from the stock’s previous […]
March 25, 2024
Barinthus Biotherapeutics (NASDAQ:BRNS – Free Report) had its price objective cut by HC Wainwright from $15.00 to $8.00 in a research report released on Thursday, Benzinga reports. They currently have a buy rating on the stock. Separately, William Blair reaffirmed an outperform rating on shares of Barinthus Biotherapeutics in a research report on Monday, January […]
February 29, 2024
Barinthus Biotherapeutics plc (NASDAQ:BRNS – Get Free Report) was the recipient of a significant drop in short interest during the month of February. As of February 15th, there was short interest totalling 14,100 shares, a drop of 55.8% from the January 31st total of 31,900 shares. Based on an average trading volume of 12,000 shares, […]
January 11, 2024
Barinthus Biotherapeutics (NASDAQ:BRNS – Get Free Report) is one of 988 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Barinthus Biotherapeutics to related businesses based on the strength of its valuation, risk, analyst recommendations, profitability, dividends, earnings and institutional ownership. Risk and Volatility Barinthus Biotherapeutics […]
January 5, 2024
Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones...
November 9, 2023
Initial data from the combination of imdusiran and VTP-300 show meaningful reductions of HBsAg levels that were maintained well below baseline.In HBV003,...